key: cord-0907088-zy7b75ai
authors: Zhang, Hui; Liu, Xingtian; Liu, Qingzhi; Mei, Hongshuang; Wang, Yashu; Cui, Gang; Zhao, Shuping
title: Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay
date: 2022-02-01
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.01.064
sha: 1406bb7245004d8ba4c44c13be55d83a3a463fb6
doc_id: 907088
cord_uid: zy7b75ai

Objectives This study aimed to explore the regularity of S-RBD domain antibody reactivity after immunization with inactivated SARS-CoV-2 vaccine and evaluate the immune response effect of this vaccine. Design or methods Venous blood samples were collected from 1156 healthcare workers who participated in the phase III clinical trial of SARS-CoV-2 inactivated vaccine. The S-RBD domain antibody levels in serum were detected by ELISA 14 days after the first and second active immunization respectively. Results The positive rate of S-RBD domain antibody against SARS-CoV-2 was 28.03% and 86.76% respectively after inoculation of the first and second vaccination. The mean inhibition rate of S-RBD domain antibody against positive samples was (57.18 ± 18.87) % after the second vaccination at 14 days. Gender and age had no effects on the positive rate. The positive rate was decreased in the high BMI group. Single-factor logistic analysis showed that there was no significant correlation between age and positive rate. BMI was negatively correlated with the positive rate. Conclusions After two times of immunization, the positive rate of SARS-CoV-2 S-RBD domain antibody was high, and the vaccine had good immunogenicity. The improvement of the immune strategy should focus on the effects of BMI and other factors.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lead to the outbreak of coronavirus disease 2019 (COVID-19) pandemic (Tsang et al. 2021 ). This infection outbreak has posed a serious threat to global trade and public health (Cutler 2020; Antia and Halloran 2021) . By November 9, 2021, the number of confirmed cases in COVID-19 has exceeded 250 million, and the number of deaths has exceeded 5 million according to the WHO. No biomarkers have been proved to be effective in the treatment of COVID-19 due to various restraints . At present, vaccination is considered to be the most effective option to prevent the prevalence of viral infection (Dagotto et al. 2020; Krammer 2020) . Neutralizing antibodies block viral infection and reflect the intensity of the body's humoral immune response (Häfner 2019) .

It has been discovered in the study that SARS-CoV-2 mainly activates intracellular 4 endocytosis through the combination of spike protein (S protein) receptor-binding region (S-RBD) and human angiotensin converting enzyme 2 (hACE2), and thus enters into human cells and initiates the related signals of virus replication (Amanat and Krammer 2020) . Thus, neutralizing antibodies against the RBD domain of S protein can block viral infection.

Protection evaluation of vaccines often requires tracking the health of the vaccinated population for several years to obtain convincing data. However, the ongoing development of the pandemic worldwide has not allowed sufficient time for adequate vaccine protection analysis Therefore, it is necessary to establish a method that can indirectly evaluate the protective effect of vaccines (Hodgson et al. 2021) .

Several detecting kits were applied in this field. Gambino et al certifies that the immunochromatographic rapid test and the chemiluminescence immunoassay have a good concordance (Gambino et al. 2020) . According to the existing research reports, detecting the level of neutralizing antibodies against the RBD domain can theoretically become indirect evidence to evaluate the effectiveness of the vaccine (Jin et al. 2021 ).

At present, there are few reports on the production of neutralizing antibodies in people immunized with SARS-CoV-2 inactivated vaccine. This study intended to detect and analyze the level of S-RBD antibodies in people who are voluntarily vaccinated with inactivated SARS-CoV-2 vaccine (Vero) in hospitals, to find out the influencing factors and rules of S-RBD antibody production, provide a reference basis for improving the immunization strategy, and provide data support for the newly established experimental method.

This study was a prospective observational cohort study. A total of 1156 healthcare workers who completed the twice immunization with inactivated SARS-Cov-2 Vaccine (Vero Cell) from Taian City Central Hospital between December 2020 and January 2021 were enrolled in this investigation. The mean age of the included subjects was 37.63 ± 10.34 years (18 -60 years), including 868 females and 288 males ( Table 1 ). The inactivated vaccine was from the Beijing Institute of Biological Products (Beijing, China). The vaccination was carried out in full accordance with Technical guidelines for vaccination in Covid-19 (中华人民共和 国国家卫生健康委员会 2021) as a two-dose regimen with an interval of 3 weeks.

All these personnel did not affect by SARS-CoV-2. The following populations were excluded: history of contact with a confirmed case of COVID-19, severe systemic immune disease, suspected symptoms of COVID-19. The venous blood was collected on the 14th day of the first and second needles inoculation, respectively. The serum specimens were collected after centrifugation for the following detection. This study was performed in accordance with the Declaration of Helsinki, the design and procedure of this study were approved by Taian City Central Hospital. All participants signed the written informed consent.

The anti-SARS-Cov-2 neutralizing antibody ELISA kits from Vazyme (Nanjing, China) were used to detect the neutralizing antibodies. The microplate was coated with recombinant human ACE2 receptor protein (hACE2) and horseradish peroxidase-labeled RBD protein (HRP-RBD) was used to prepare the enzyme 6 conjugate. In the first step of the reaction, the sample was preincubated with HRP-RBD outside the ELISA plate at 37℃ for 30 minutes. And then, the previous mixture was transferred into the hACE2-coated plate and incubated for 20 minutes, where HRP-RBD without binding to the neutralizing antibody binds to hACE2. After washing, the TMB substrate was added, and the substrate produced a colored product under the action of enzyme. After termination, the absorbance value was immediately read at the wavelength of 450 nm. The absorbance is inversely proportional to the effective activity of the anti-RBD neutralizing antibody in the sample. The signal inhibition rate (SIR) was calculated with the equation, that is, SIR = (1-OD of sample/mean OD of negative control) ×100%. The SIR ＜ 20% indicated that neutralizing antibody was absent and the SIR ≥ 20% indicated the presence of SARS-CoV-2 neutralizing antibody.

SPSS21.0 statistical software and GraphPad were used for data processing and statistical analysis. The counting data were expressed in the number of cases or percentages. The student T-test, ANOVA, and χ 2 test were used for comparison among groups. The single factor logistic regression was used to analyze the correlations between SIR and clinical characteristics. The difference was statistically significant (P < 0.05). As shown in Figure 2B , age could not influence the levels of SIR in samples of positive individuals (P > 0.05).

According to the quartile of BMI, the patients were divided into four groups: ≤ 21.00 kg/m 2 , 21.00-25.00 kg/m 2 , and > 25.00 kg/m 2 . The results showed that there was a significant difference in the positive rate among different groups (Table 2, P < 0.05). In addition, in Figure 2C , the SIR values in the 21.00-25.00 kg/m 2 and > 25.00 kg/m 2 group were decreased compared to the ≤ 21.00 kg/m 2 group (P < 0.05). The average SIR value was decreased in the > 25.00 kg/m 2 group compared with the 21.00-25.00 kg/m 2 group (Figure 2C , P < 0.05). 8 

Univariate logistic analysis with novel coronavirus S-RBD domain antibody positive as dependent variable and characteristics as independent variable respectively. Table 3 , there was no significant correlation between positive rate and gender (OR = 1.005, 95%CI = 0.678-1.489, P = 0.981) and age (OR = 1.012, 95%CI = 0.995-1.029, P = 0.170). In addition, there was a significant negative correlation between BMI and positive rate ( Table 3 , OR = 0.930, 95%CI = 0.902-0.959, P < 0.01).

Since the outbreak of the novel coronavirus epidemic, it has posed a serious threat to the life safety, and health of the people and has brought a great impact on the development of the world economy (Niu et al. 2020; Li XZ et al. 2021) . At present, the international epidemic situation still continues to spread at a high rate, and China's epidemic prevention and control have achieved significant results, however, the import of overseas epidemic diseases poses a greater risk of local spread ).

Recently, imported epidemic diseases causing local epidemic spread have been reported in some parts of China, resulting in the serious situation of normalized epidemic prevention and control in winter and spring. Vaccination is a powerful measure to address and control further transmission and outbreaks in COVID-19(Monrad 2020).

On the basis of ensuring safety, effectiveness is a key indicator to evaluate whether a vaccine can be marketed, and the intensity and durability of the immune response are also key indicators to evaluate the effectiveness of a vaccine (Mao et al. 2013) . The results of this study showed that 14 days after the first dose of inoculation, the positive 9 rate of novel coronavirus S-RBD domain antibody was 28.03%, and the average It has been reported that there is no difference in IgG antibody concentration between mild, normal, and recovered male and female patients (Huang et al. 2020; Jiang et al. 2020; Zeng et al. 2020) . The incidence and mortality of severe cases in male patients are higher than those in female patients, and the possible underlying reasons

are not yet clear (Sohn et al. 2021 ). However, the dynamics of the SARS-CoV-2 IgG antibody were different between male and female patients (Zeng et al. 2020) . Therefore, 10 the dynamic change of antibody level may be the reason that affects the incidence and mortality of severe diseases. Comparing the positive rate and inhibition rate of S-RBD domain antibodies between men and women in the immunized population, it was found that there was no statistical difference. The subsequent dynamic changes of the S-RBD domain antibody still needed to be tracked and detected. In addition, this study was divided into four groups according to age quartile. The results showed that there was no significant difference in the positive rate between groups. Univariate logistic analysis showed that there was no significant correlation between age and positive rate, indicating SARS-CoV-2 inactivated vaccine could get an ideal humoral immune effect in all age groups of 20-60 years old.

Studies have found that obese people have an increased risk of serious COVID-19 (Caci et al. 2020) . The body mass index is commonly used internationally to measure the degree of obesity and health . A large meta-analysis of 75 studies shows that obesity may be an important risk factor affecting the clinical outcomes of SARS-CoV-2 pneumonia (Aminian and Tu 2021) . In this study, with the increase of BMI, the positive rate showed a significant downward trend. Additionally, BMI was in a significant negative correlation of the positive rate. It could be deduced that BMI might be an important factor on regulating the levels of S-RBD domain antibody in the immune population. According to the grouping comparison results, BMI should be considered as an important factor in planning immune strategy to achieve better humoral immunity. However, the mRNA BNT162b2 vaccines from Pfizer-BioNTech show age-, time-and sex-related differences after administration (Lo Sasso et al. 2021 ). This conclusion was inconsistent with our findings, which might be due to the fact that we used inactivated vaccine whereas the mRNA vaccine was used in the above article.

The production of an antibody response is generally one of the manifestations of vaccine protection efficacy. Based on the results of existing research, the ability of human body to produce Covid-19-related antibody after inoculation with this vaccine is ideal. Of course, this is not entirely equivalent to vaccine effectiveness being desirable.

Whether the S-RBD domain antibody captured by the experimental method is a valid neutralizing antibody, especially for the validity of recently reported SARS-CoV-2 variants in various countries, and other aspects, need to be verified by further pseudovirus and true virus experiments. Therefore, ongoing monitoring and further analysis of S-RBD domain antibody levels in the vaccinated population are still needed.

In conclusion, we analyzed the reaction law of the population producing antibodies against the RBD domain after immunization with SARS-CoV-2 inactivated vaccine.

These results indicated that the inactivated SARS-CoV-2 vaccine could induce a high level of S-RBD domain antibody response, independent of gender and age. In addition, BMI might influence the level of S-RBD domain antibody produced by SARS-CoV-2 inactivated vaccine.

None.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The difference in SIR according to gender, age, and BMI. A The SIR results of sex. B The comparison of SIR in different age groups. C Different SIRs in the different BMI groups. *P < 0.05, ***P < 0.001, compared with the ≤ 21.00 group; # P < 0.05, compared with the 21.00-25.00 group. 

SARS-CoV-2 Vaccines: Status Report

Association of Bariatric Surgery with Clinical Outcomes of SARS-CoV-2 Infection: a Systematic Review and Meta-analysis in the Initial Phase of COVID-19 Pandemic

Transition to endemicity: Understanding COVID-19

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Annals of laboratory medicine

COVID-19 and Obesity: Dangerous Liaisons

How Will COVID-19 Affect the Health Care Economy?

Approaches and Challenges in SARS-CoV-2 Vaccine Development

of anti-SARS-CoV-2 IgM and IgG

Guns N' viruses. Microbes and infection

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious diseases

Clinical features of patients infected with 2019 novel coronavirus in

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal transduction and targeted therapy

SARS-CoV-2 vaccines in development

Modeling and Research on an

Immuno-Epidemiological Coupled System with Coinfection

What is the status of nucleic acid contamination in 2019-nCOV vaccination sites? Can it be avoided? Epidemiology and infection

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children

Ethical considerations for epidemic vaccine trials

Clinical characteristics of older patients infected with COVID-19: A descriptive study. Archives of gerontology and geriatrics

Intranasal Protection and Differential Sex Pathology in a Murine 15 Model of SARS-CoV-2 Infection. mBio

An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex

Health risk assessment of PM(2.5) on walking trips

The research was supported by Dr. Jinpeng Bi from Nanjing Nazyme Biotechnology Co., Ltd.

This study was performed in accordance with the Declaration of Helsinki, the design and procedure of this study were approved by Taian City Central Hospital. All participants signed the written informed consent.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: